Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients with Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
Analysis of REDUCE-IT study of icosapent ethyl in statin-treated people with elevated triglycerides who had CVD or diabetes and one additional risk factor found it reduced the primary and secondary composite endpoints across eGFR categories.
Source:
Circulation
SPS commentary:
Another analysis from this study reports findings from the subgroup of patients with history of CABG, in which a reduction in the primary endpoint was also noted (HR 0.76; 95% CI 0.63-0.92; P=0.004).